Simcere Pharmaceutical has launched a Phase II clinical trial for regulatory T-cell (Treg)-selective IL-2 mutant fusion protein SIM0278 in moderate-to-severe atopic dermatitis, following positive Phase I data showing favourable pharmacokinetics and safety profile. The randomised double-blind placebo-controlled multicentre study evaluates the subcutaneous injection in restoring immune balance through preferential activation of Tregs over effector T-cells and natural killer (NK) cells. The candidate utilises protein engineering mutations reducing effector T-cell affinity while maintaining Treg binding.

Investigators highlighted the Treg peripheral tolerance mechanism as a key immunological breakthrough supporting therapeutic potential in autoimmune conditions. Simcere partnered with Almirall in 2022 granting ex-China rights for dermatology indications, with US Phase I completion and planned Phase II initiation in additional skin diseases. SIM0278 demonstrates best-in-class potential with durable efficacy profile and optimised dosing regimen, supporting advancement across multiple immune dysregulation conditions including atopic dermatitis.

PharmCube's NextBiopharm® database shows that SIM0278 leads globally in terms of development among IL-2-targeted fusion proteins. Click here to request a free trial for NextBiopharm®.